SIGN UP
LOG IN
MARKET
SLN
SLN
Silence Therapeutics Plc
NASDAQ
22.64
+0.62
+2.82%
After Hours: 22.64 0 0.00% 16:00 04/19 EDT
OPEN
21.76
PREV CLOSE
22.02
HIGH
23.18
LOW
21.76
VOLUME
305.74K
TURNOVER
0
52 WEEK HIGH
27.72
52 WEEK LOW
4.545
MARKET CAP
1.05B
P/E (TTM)
-47.3838
1D
5D
1M
3M
1Y
5Y
Silence Therapeutics Announces Upcoming AGM
Silence Therapeutics Plc is set to hold its Annual General Meeting (AGM) on May 17, 2024. The meeting can be attended in person in Hoboken, NJ, and virtually via the Lumi Meeting Platform. SLN stock is down 7% in the last week.
TipRanks · 4d ago
Weekly Report: what happened at SLN last week (0408-0412)?
Weekly Report · 4d ago
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
NASDAQ · 04/12 12:21
Silence Therapeutics Announces JAMA Publication Of Additional APOLLO Phase 1 Data For Zerlasiran In Subjects With Elevated Lipoprotein(a)
Zerlasiran is a siRNA designed to lower the body's production of lipoprotein(a), a key genetic risk factor for cardiovascular disease. The study was published in the Journal of the American Medical Association. The company is currently conducting a phase 2 study.
Benzinga · 04/08 15:49
Weekly Report: what happened at SLN last week (0401-0405)?
Weekly Report · 04/08 09:50
Weekly Report: what happened at SLN last week (0325-0329)?
Weekly Report · 04/01 09:50
Weekly Report: what happened at SLN last week (0318-0322)?
Weekly Report · 03/25 09:51
Weekly Report: what happened at SLN last week (0311-0315)?
Weekly Report · 03/18 09:50
About SLN
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
Webull offers Silence Therapeutics plc stock information, including NASDAQ: SLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading SLN stock methods without spending real money on the virtual paper trading platform.